Bottom line
TICCX vs IGIB: the short answer
TICCX (T. Rowe Price Corporate Income Fund, Inc.) and IGIB (iShares 5-10 Year Investment Grade Corporate Bond ETF) are both mutual funds.
But IGIB is far broader, holding 2,990 positions to 330 for TICCX, so beyond the top names it adds exposure TICCX doesn't have.
IGIB is cheaper at 0.04% vs 0.4% — a difference of $36 a year per $10,000 invested.
Over five years, IGIB returned +1.0% a year vs +0.0% for TICCX.
Updated Nov 19, 2026
TICCX vs IGIB side by side
| TICCX | IGIB | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | T. Rowe Price | iShares |
| Category | Corporate Bond | Corporate Bond |
| Expense ratio | 0.4% | 0.04% |
| Annual cost per $10k | $40 | $4 |
| 10-yr cost on $10k (prospectus) | $641 | $51 |
| Max front load | — | None |
| 12b-1 fee | — | — |
| 1-yr return | +8.0% | +9.6% |
| 5-yr return (annualized) | +0.0% | +1.0% |
| 10-yr return (annualized) | +3.1% | +3.4% |
| Best quarter | +10.0% | +10.3% |
| Worst quarter | −8.3% | −7.0% |
| Net assets (fund) | $284.3M | $18.2B |
| Number of holdings | 330 | 2,990 |
| Portfolio turnover | 113% | 27% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
TICCX and IGIB share none of their top holdings.
TICCX top 10
- Grs - Security Lending Collateral — 2.32%
- Citigroup Inc — 2.11%
- US Treasury N/b — 1.59%
- Goldman Sachs Group Inc — 1.33%
- At&t Inc — 1.28%
- Morgan Stanley — 1.27%
- US Treasury N/b — 1.21%
- Cvs Health Corp — 1.06%
- Sonic 2020-1a A2i 144a — 1.04%
- Yara International Asa 144a — 1.03%
IGIB top 10
- BlackRock Funds III — 11.07%
- Meta Platforms Inc — 0.23%
- Amazon.com Inc — 0.22%
- Anheuser-busch Co/inbev — 0.20%
- Bank Of America Corp — 0.19%
- Bank Of America Corp — 0.19%
- Bank Of America Corp — 0.19%
- Mars Inc — 0.19%
- Pfizer Investment Enter — 0.18%
- Jpmorgan Chase & Co — 0.18%
FAQ
What is the difference between TICCX and IGIB?
Which is cheaper, TICCX or IGIB?
Should I own both TICCX and IGIB?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.